Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from 25 April to 03 May 2024.The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time.Powered by Capital Market - Live News

Aurobindo Pharma announced that Aurogen South Africa, South Africa, a wholly owned step-down subsidiary of the Company, has entered into agreement with the shareholders of Purple Bellflower (PBF), South Africa, a joint venture company, to purchase entire shares held by other joint venture partners and make Purple Bellflower a wholly owned subsidiary of Aurogen South Africa, and also Aurobindo Pharma, South Africa, a wholly owned subsidiary of Aurogen South Africa.48% shares of PBF are held by Aurogen South Africa, South Africa (ASL), a wholly owned step-down subsidiary of the Company and 52% shares are held by other Joint Venture Partners. Powered by Capital Market - Live News

Aurobindo Pharma has completed the disposal of business assets of Eugia US Manufacturing LLC, a wholly owned step- down subsidiary of the company on 01 May 2024. Powered by Capital Market - Live News

Aurobindo Pharma announced that on 06 April 2024 at around 11:30 PM (IST), an accident occurred near Vacuum Tray Dryer (VTD) area at Unit 6 of Apitoria Pharma, situated at Parawada, Anakapalli District, Andhra Pradesh. Unfortunately, there was one casualty due to the accident. The unit continues its normal operations. Powered by Capital Market - Live News

Aurobindo Pharma has appointed T. Vijaya Kumar as President � R&D (Specialty Drug Delivery) effective 05 April 2024. Accordingly, T. Vijaya Kumar will be part of the Senior Management team of the Company. Powered by Capital Market - Live News